Peterson, Laura S.
Stelzer, Ina A.
Tsai, Amy S.
Ghaemi, Mohammad S.
Han, Xiaoyuan
Ando, Kazuo
Winn, Virginia D.
Martinez, Nadine R.
Contrepois, Kevin
Moufarrej, Mira N.
Quake, Stephen
Relman, David A.
Snyder, Michael P.
Shaw, Gary M.
Stevenson, David K.
Wong, Ronald J.
Arck, Petra
Angst, Martin S.
Aghaeepour, Nima
Gaudilliere, Brice http://orcid.org/0000-0002-3475-5706
Funding for this research was provided by:
March of Dimes Prematurity Research Center- Stanford (22-FY18-808)
Maternal and Child Health Research Initiative, Stanford University
Doris Duke Charitable Foundation (2018100)
National Institutes of Health (RO1HL13984401)
Bill and Melinda Gates Foundation (OPP1189911)
Mary L. Johnson Research Fund
Christopher Hess Research Fund (N/A)
Article History
Received: 26 July 2019
Accepted: 31 October 2019
First Online: 4 February 2020
Compliance with ethical standards
:
: D.A.R holds stock in Seres Therapeutics and Evelo Bioscences and stock options in ArcBio, Karius, NanoBio, ProdermIQ, and Second Genome. M.P.S is a cofounder and on the Scientific Advisory board of the following: Personalis, Qbio, SensOmics, January, Mirvie, and Filtricine. M.P.S is on the scientific advisory board of the following: Genapsys and Jupiter. Authors M.N.M and S.R.Q are inventors on a patent on cfRNA associated with article by Ngo et al. cited in this text (ExternalRef removed). S.Q. is founder, shareholder and board member of Mirvie.